Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose of RX-0201, up to a target dose of 250 mg/m^2/day, when given in combination with everolimus (Stage 1), and to assess the safety and efficacy of RX-0201 plus everolimus, in subjects with metastatic renal cell cancer (Stage 2).


Clinical Trial Description

This multi-center, open-label, randomized, parallel group study of RX-0201 in combination with everolimus, versus everolimus alone to treat subjects with advanced renal cell carcinoma will be conducted in 2 stages. Stage 1 will be an open-label, dose-escalation study of RX-0201 to identify a safe and tolerable dose of RX-0201 up to a target dose of 250 mg/m^2/day when given in combination with everolimus. Stage 2 will be a randomized, open-label, 2-arm study of RX-0201 in combination with everolimus versus everolimus alone. Subjects will receive RX-0201, at the dose identified in Stage 1, in combination with everolimus or everolimus alone, for up to 8 cycles to determine safety and efficacy of the combination. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02089334
Study type Interventional
Source Rexahn Pharmaceuticals, Inc.
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date August 2014
Completion date May 17, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02664883 - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01462214 - Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer Phase 1/Phase 2
Completed NCT02555748 - Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Phase 4
Completed NCT02899078 - Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT00670748 - Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer Phase 2
Completed NCT01829841 - A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer Phase 2
Active, not recruiting NCT01767636 - Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Phase 2
Terminated NCT02542202 - Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer N/A
Completed NCT02626130 - Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer Early Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Active, not recruiting NCT01590069 - Aerosolized Aldesleukin in Treating Patients With Lung Metastases Phase 1
Recruiting NCT01884961 - Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 Phase 2
Completed NCT02599194 - 18F-FSPG PET/CT for Cancer Patients on Therapy Phase 2
Completed NCT01246843 - Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib N/A
Completed NCT01258348 - A Phase 1b Trial in Patients With Renal Cell Cancer Phase 1
Completed NCT00428220 - A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. N/A
Active, not recruiting NCT03092856 - Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Phase 2
Completed NCT02843607 - Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer Phase 1/Phase 2
Completed NCT02318771 - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Phase 1